<DOC>
	<DOCNO>NCT00628420</DOCNO>
	<brief_summary>To determine safety tolerability ACP-104 oral administration single dos comparison placebo schizophrenia psychotic disorder .</brief_summary>
	<brief_title>Safety Study ACP-104 : To Demonstrate Safety , Tolerability , Pharmacokinetics</brief_title>
	<detailed_description>Thirty-six healthy patient schizophrenia psychotic disorder , drug-free study initiation , admit hospital receive two dos ACP-104 , one dose placebo , orally every 3-5 day two-week period . The patient divide six group six minimum 3 patient . Group 1 consist six patient receive single 25mg 50mg dos ACP-104 placebo random , rise dose , order two-week period . Data group one collect determine ACP-104 's safety , tolerability , pharmacokinetics . Group 2 enrol study study data Group 1 demonstrate safety ACP-104 . Group 2 receive 25mg pre-conditioning dose ACP-104 . Following pre-conditioning dose , 75mg 100mg single dos ACP-104 administer random , rise dose , order , two-week period . Group 3 enrol study study data Group 2 demonstrate safety ACP-104 . Group 3 receive 25mg pre-conditioning dose ACP-104 . Following pre-conditioning dose , 125mg 150mg single dos ACP-104 administer random , rise dose , order , two-week period . Group 4 enrol study study data Group 3 demonstrate safety ACP-104 . Group 4 receive 25mg pre-conditioning dose ACP-104 . Following pre-conditioning dose , 175mg 200mg single dos ACP-104 administer random , rise dose , order , two-week period . Group 5 enrol study study data Group 4 demonstrate safety ACP-104 . Group 5 receive 25mg pre-conditioning dose ACP-104 . Following pre-conditioning dose , 225mg 250mg single dos ACP-104 administer random , rise dose , order , two week period . Group 6 enrol study study data Group 5 demonstrate safety ACP-104 . Group 6 receive 25mg pre-conditioning dose ACP-104 . Following pre-conditioning dose , 275mg 300mg single dos ACP-104 administer random , rise dose , order , two-week period . Groups 1-6 monitor closely safety procedure evaluation perform medication day . Safety assessment include : physical examination , vital sign ( 3-positional blood pressure pulse rate , respiration rate , oral body temperature ) , clinical laboratory test , ECGs ( Electrocardiogram ) , coordination test , question symptom side effect . Once medication day complete , condition patient assess , , time , determine whether patient 's condition suitable release hospital whether monitor patient 's condition inpatient need .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Males female , surgically sterilize least 1 year post menopausal , good health ( base medical history , physical examination , electrocardiogram , clinical laboratory test ) Between 20 50 year old ( inclusive ) History schizophrenia , schizoaffective disorder , bipolar psychosis , major depression psychosis , PTSD psychosis , psychosis NOS experience acute exacerbation severe psychosis Able execute inform write consent Willing follow dietary restriction outline Section 6.2 General dietary restriction , Willing remain hospitalized inpatient portion study return follow visit ( ) require protocol deem necessary principal investigator , Will need treatment antipsychotic medication , Fluent literate English Any patient receive clozapine within last three month , depot antipsychotic within last six month , Likely allergy insensitivity ACP104 clozapine base know allergy drug class , opinion principle investigator , suggest increase potential adverse hypersensitivity ACP104 Any prior history druginduced leukopenia neutropenia , Any prior history neuroleptic malignant syndrome History seizure , epilepsy , severe head injury , multiple sclerosis , know neurological condition Prior history cardiovascular disease , include arrhythmia myocarditis Abnormal preadmission vital sign clinical laboratory evaluation Any patient history , within last three month , alcohol and/or drug dependency alcohol and/or drug abuse last month History hepatic renal disease Any patient schedule undergo surgical procedure duration study , Any patient take concurrent medication major medical illness Any patient donate plasma blood within 30 day first dose study medication , Any patient receive know hepatic renal clearance alter agent ( e.g. , erythromycin , cimetidine , barbiturate , phenothiazine , etc . ) period 3 month first dose study medication Ingestion use investigational medication device within 3 month first dose study medication Acute illness within 5 day first dose study medication Mental capacity limit extent patient provide legal consent understand information regard side effect tolerance study drug Any patient judge principal investigator inappropriate study . We resource necessary properly study nonEnglish speaking patient study . The need provide resource would prohibitive successful completion study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>N-desmethylclozapine</keyword>
	<keyword>clozapine</keyword>
	<keyword>psychosis</keyword>
	<keyword>randomize</keyword>
	<keyword>placebo study</keyword>
</DOC>